Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc

KNSA

Rang in Aktien #2962
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aktienkurs
$79.61
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$6.21B
Veränderung (1 Tag)
1.30%
Veränderung (1 Jahr)
104.18%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)

Kategorie

Healthcare
Dividendenrendite-Verlauf für Kiniksa Pharmaceuticals International, plc (KNSA)
Dividendenrendite (TTM) von Kiniksa Pharmaceuticals International, plc (Aktienkürzel: KNSA) zum 2023-12-31: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Kiniksa Pharmaceuticals International, plc (KNSA) von 2016 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber